DIAGNOCURE TO HOST Q2 2011 CONFERENCE CALL AND WEBCAST

QUEBEC CITY, May 27, 2011 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its second quarter 2011 results on June 6, 2011, at approximately 4:30 p.m. (EDT). This release will be followed by a conference call, which will be held on June 7, 2011, at 9:00 a.m. (EDT). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations.

For those who wish to take part in the conference call for the Q&A period, please dial the phone number, provide the subject «DiagnoCure Q2 earnings announcement» and the Conference ID: 4441362. Access phone numbers for participants from Montreal is 514-807-8791 and for other participants the toll-free number is 1-800-732-1073.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of June 8, 2011, also through a link on the Investors page - Presentations.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure, Inc., launched in 2008 the PrevistageTM GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. To date, two major studies (JAMA 2009 and Ann Surg Onc. 2011) have demonstrated that the GCC biomarker, to which DiagnoCure owns exclusive worldwide diagnostic rights, of all the risk factors compared in the studies is the strongest independent predictor of colorectal cancer recurrence. The Company has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is available through laboratories in the U.S. and in Canada using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA® PCA3 in vitro assay. Gen-Probe completed a 500-patient clinical study aimed at securing FDA approval for the commercialization of the PROGENSA® PCA3 test in the U.S. and filed a PMA in September 2010. For more information, visit www.diagnocure.com.

Forward‐looking statements

This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DIAGNOCURE INC.

For further information:

Investors     
DiagnoCure Inc.
Chantal Miklosi
Chief Financial Officer
(418) 527-6100
communications@diagnocure.com 
  Media     
DiagnoCure Inc.
Paule De Blois
Senior Vice President, Operations
 (418) 527-6100
communications@diagnocure.com

 

Profil de l'entreprise

DIAGNOCURE INC.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.